FunPep's Hay-Fever Vaccine Passes Safety Test, Misses Symptom Goal
FunPep's FPP004X hit its safety and antibody-response targets in a Phase 1 trial, with titers rising in 97 to 100 percent of subjects, but an exposure-chamber test found no symptom improvement over placebo, and the split result now goes to option-holder Shionogi for discussion on what comes next.